GENSPEED Biotech ’s Post

𝐍𝐞𝐰 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞 𝐨𝐟 𝐆𝐄𝐍𝐒𝐏𝐄𝐄𝐃’𝐬 𝐮𝐧𝐢𝐪𝐮𝐞 𝐜𝐚𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬! 🍾🍾 In our latest 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐁𝐨𝐧𝐞 𝐚𝐧𝐝 𝐉𝐨𝐢𝐧𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 conducted in collaboration with the esteemed team at 𝐂𝐡𝐚𝐫𝐢𝐭é – 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭ä𝐭𝐬𝐦𝐞𝐝𝐢𝐳𝐢𝐧 𝐁𝐞𝐫𝐥𝐢𝐧- we showcase how our rapid multiplex micro-ELISA can simultaneously measure alpha-defensin, calprotectin, and IL-6 in a single, 20-minute test using just microliters of synovial fluid. This 𝐭𝐡𝐫𝐞𝐞-𝐢𝐧-𝐨𝐧𝐞 𝐚𝐬𝐬𝐚𝐲 has the potential to be a future game changer for diagnosing periprosthetic joint infection (PJI), providing faster, more precise results at the point of care. What makes it exceptional: • 𝐔𝐧𝐢𝐪𝐮𝐞 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞𝐱𝐢𝐧𝐠 of three biomarkers in one test • 𝐅𝐚𝐬𝐭 𝐓𝐮𝐫𝐧𝐚𝐫𝐨𝐮𝐧𝐝 for more immediate treatment decisions • 𝐋𝐨𝐰 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐋𝐢𝐦𝐢𝐭𝐬 - well below established PJI thresholds • 𝐏𝐚𝐭𝐢𝐞𝐧𝐭-𝐂𝐞𝐧𝐭𝐞𝐫𝐞𝐝: Earlier, more accurate diagnosis can reduce hospital stays and improve outcomes We’re excited for the broader impact this technology can have, once clinically validated, on patients worldwide. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐨𝐩𝐞𝐧-𝐚𝐜𝐜𝐞𝐬𝐬 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐡𝐞𝐫𝐞: https://lnkd.in/dNE5UXcn